ÂÜÀòÂÒÂ×

Michael Lewis is a Scientist II at Life Edit Therapeutics, with previous experience as a Postdoctoral Researcher at the University of North Carolina at Chapel Hill, where research focused on the epigenetics of breast cancer, particularly the role of eRNA producing enhancers in triple negative breast cancer. Prior positions include a Postdoctoral Researcher at the University of Florida, analyzing the Angelman syndrome imprinting defect mouse model, and conducting PhD research on genomic imprinting mechanisms at the Prader-Willi/Angelman syndrome locus. Michael's academic background includes a Ph.D. in Medical Sciences - Genetics and a B.S. in Microbiology and Cell Sciences from the University of Florida, in addition to an A.A. from St. John's River State College.